Advances in X chromosome inactivation open therapeutic opportunities for X-linked genetic disorders

https://www.news-medical.net/news/20260803/Advances-in-X-chromosome-inactivation-open-therapeutic-opportunities-for-X-linked-genetic-disorders.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=rare_diseases_newsletter_10_august_2026 A new review explores how advances in understanding X chromosome inactivation (XCI) are creating potential therapeutic opportunities for a range of X-linked genetic disorders, including Rett syndrome, Fabry disease, Duchenne muscular dystrophy, hemophilia, and others. The article examines the molecular mechanisms that control X chromosome silencing, the impact of skewed XCI on disease severity, emerging methods to measure XCI patterns, and experimental approaches aimed at reactivating beneficial genes on the inactive X chromosome.

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone

Ion channel TPC1 identified as key regulator of iron homeostasis

https://www.news-medical.net/news/20260806/Ion-channel-TPC1-identified-as-key-regulator-of-iron-homeostasis.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=pharmacy_and_pharmacology_newsletter_14_august_2026

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD

https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_stan_mscpedu_260816-OUS-HONC-enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46-cta&uac=148436CN

Society for Pediatric Dermatology (SPD) 2026 Annual Meeting +...

https://www.medscape.com/c25/p14/society-pediatric-dermatology-spd-2026-annual-meeting-2026a1000mgj?ecd=wnl_conf_derm_SPD_NON-SPON_260811_mscpedit_conf1_etid8584150&uac=148436CN&impID=8584150

HMGCR emerges as a promising target for precision cancer therapies + + +

HMGCR emerges as a promising target for precision cancer therapies https://www.news-medical.net/news/20260805/HMGCR-emerges-as-a-promising-target-for-precision-cancer-therapies.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 HMGCR emerges as a promising target for precision cancer therapiesA growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape. Tuft cell-like cancers exhibit unique biological characteristics across multiple organs https://www.news-medical.net/news/20260806/Tuft-cell-like-cancers-across-multiple-organs-exhibit-unique-biological-characteristics.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Tuft cell-like cancers exhibit unique biological characteristics across multiple organsA growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized. Early radionuclide therapy delays progression in metastatic prostate cancer https://www.news-medical.net/news/20260806/Early-radionuclide-therapy-delays-progression-in-metastatic-prostate-cancer.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment + + + + +

https://www.news-medical.net/news/20260806/Ferroptosis-based-therapy-shows-promise-for-advanced-prostate-cancer-treatment.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC). The authors synthesize current knowledge of ferroptosis mechanisms, biomarkers, therapeutic agents, combination strategies, and translational challenges, proposing a framework that links ferroptosis regulatory networks with precision medicine approaches. Tadalafil may increase glaucoma risk in men with enlarged prostates https://www.news-medical.net/news/20260804/Tadalafil-may-increase-glaucoma-risk-in-men-with-enlarged-prostates.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 An erectile dysfunction drug that is also used to treat symptoms like sudden urgency and frequency, which are associated with an enlarged prostate in men, may heighten the risk of the serious eye condition, glaucoma, finds a large comparative study published online in the British Journal of Ophthalmology. Older men’s sexual priorities extend well beyond erectile function https://www.news-medical.net/news/20260806/Older-mene28099s-sexual-priorities-extend-well-beyond-erectile-function.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 A web-based survey of 6,000 Japanese men aged 50 or older found that sexual arousal was the function they most wanted to preserve, while erection became more highly valued as erectile function worsened. Erection showed the earliest age-related decline pattern, whereas ejaculation was the function most often reported as lost in older age. AI tool helps customize radiopharmaceutical therapy dosingAI tool helps customize radiopharmaceutical therapy dosing https://www.news-medical.net/news/20260804/AI-tool-helps-customize-radiopharmaceutical-therapy-dosing.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress-and billions of dollars of industry investments-one area that has lagged behind is dosing, which is still one-size-fits-all. Study identifies a novel direct drug target for head and neck squamous cell carcinomaStudy identifies a novel direct drug target for head and neck squamous cell carcinoma https://www.news-medical.net/news/20260806/Study-identifies-a-novel-direct-drug-target-for-head-and-neck-squamous-cell-carcinoma.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.